{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,5,29]],"date-time":"2026-05-29T23:04:02Z","timestamp":1780095842744,"version":"3.54.0"},"reference-count":21,"publisher":"Georg Thieme Verlag KG","issue":"12","content-domain":{"domain":[],"crossmark-restriction":false},"short-container-title":["Dtsch Med Wochenschr"],"published-print":{"date-parts":[[2026,6]]},"abstract":"<jats:title>Was ist neu?<\/jats:title>\n                  <jats:p>Die Acetylcholinesterasehemmer Rivastigmin, Galantamin und Donepezil sowie der NMDA-Rezeptor-Agonist Memantin k\u00f6nnen bei vaskul\u00e4rer Demenz eingesetzt werden (Off-Label). Lecanemab und Donanemab, beides Antik\u00f6rper gegen beta-Amyloid, wurden als krankheitsmodifizierende Therapie zur Behandlung des Mild Cognitive Impairment (MCI) und leichter Demenz bei Alzheimerkrankheit zugelassen.<\/jats:p>\n                  <jats:p>K\u00f6rperliches Training bei MCI und Demenz ist potenziell in der Lage, die kognitiven Leistungen zu verbessern. Die Trainingsdauer sollte idealerweise bei 150 Minuten moderatem Training pro Woche liegen.<\/jats:p>\n                  <jats:p>Die Demenzerkrankung hat tiefgreifende Auswirkungen auf die Patient*innen und ihre Angeh\u00f6rigen. Eine m\u00f6glichst fr\u00fche Identifikation kognitiver Beeintr\u00e4chtigungen mit Hilfe multidimensionaler geriatrischer Assessments und damit eine stadiengerechte Therapieplanung ist von zentraler Bedeutung.<\/jats:p>","DOI":"10.1055\/a-2676-7649","type":"journal-article","created":{"date-parts":[[2026,5,29]],"date-time":"2026-05-29T22:38:29Z","timestamp":1780094309000},"page":"606-611","source":"Crossref","is-referenced-by-count":0,"title":["Update Antidementiva im Alter"],"prefix":"10.1055","volume":"151","author":[{"given":"Marlena","family":"Schnieder","sequence":"additional","affiliation":[{"name":"Universit\u00e4tsmedizin G\u00f6ttingen, Niedersachsen, Germany","place":["Gottingen"],"department":["Klinik f\u00fcr Geriatrie"]}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Christine","family":"von Arnim","sequence":"additional","affiliation":[{"name":"Universit\u00e4tsmedizin G\u00f6ttingen, Niedersachsen, Germany","place":["Gottingen"],"department":["Klinik f\u00fcr Geriatrie"]}],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"194","published-online":{"date-parts":[[2026,5,29]]},"reference":[{"key":"ref1","doi-asserted-by":"publisher","first-page":"e105","DOI":"10.1016\/S2468-2667(21)00249-8","article-title":"Estimation of the global prevalence of dementia in 2019 and forecasted prevalence in 2050: an analysis for the Global Burden of Disease Study 2019","volume":"7","author":"E Nichols","year":"2022","journal-title":"The Lancet Public Health"},{"key":"ref2","doi-asserted-by":"publisher","DOI":"10.1016\/j.ebiom.2025.105950","article-title":"Broadening dementia risk models: building on the 2024 Lancet Commission report for a more inclusive global framework","volume":"120","author":"CM Mostert","year":"2025","journal-title":"EBioMedicine"},{"key":"ref3","doi-asserted-by":"publisher","first-page":"5143","DOI":"10.1002\/alz.13859","article-title":"Revised criteria for diagnosis and staging of Alzheimer\u2019s disease: Alzheimer\u2019s Association Workgroup","volume":"20","author":"CR Jack Jr","year":"2024","journal-title":"Alzheimers Dement"},{"key":"ref4","doi-asserted-by":"publisher","first-page":"159","DOI":"10.1111\/cns.12484","article-title":"Role of Donepezil in the Management of Neuropsychiatric Symptoms in Alzheimer\u2019s Disease and Dementia with Lewy Bodies","volume":"22","author":"J Cummings","year":"2016","journal-title":"CNS Neurosci Ther"},{"issue":"02","key":"ref6","doi-asserted-by":"publisher","first-page":"133","DOI":"10.2174\/1567205019666220120112301","article-title":"Comparative Efficacy and Acceptability of Cholinesterase Inhibitors and Memantine Based on Dosage in Patients with Vascular Cognitive Impairment: A Network Meta-analysis","volume":"19","author":"X Shi","year":"2022","journal-title":"Curr Alzheimer Res"},{"key":"ref7","doi-asserted-by":"publisher","first-page":"375","DOI":"10.2165\/00023210-200115050-00004","article-title":"Pharmacodynamic-Tolerability Relationships of Cholinesterase Inhibitors for Alzheimer\u2019s Disease","volume":"15","author":"BP Imbimbo","year":"2001","journal-title":"Mol Diag Ther"},{"key":"ref8","doi-asserted-by":"publisher","first-page":"9","DOI":"10.1056\/NEJMoa2212948","article-title":"Lecanemab in Early Alzheimer\u2019s Disease","volume":"388","author":"van Dyck CH","year":"2023","journal-title":"N Engl J Med"},{"key":"ref9","doi-asserted-by":"publisher","first-page":"512","DOI":"10.1001\/jama.2023.13239","article-title":"Donanemab in Early Symptomatic Alzheimer Disease: The TRAILBLAZER-ALZ 2 Randomized Clinical Trial","volume":"330","author":"JR Sims","year":"2023","journal-title":"JAMA"},{"key":"ref10","doi-asserted-by":"publisher","first-page":"461","DOI":"10.1001\/jamaneurol.2025.0065","article-title":"Amyloid-Related Imaging Abnormalities With Donanemab in Early Symptomatic Alzheimer Disease: Secondary Analysis of the TRAILBLAZER-ALZ and ALZ 2 Randomized Clinical Trials","volume":"82","author":"JA Zimmer","year":"2025","journal-title":"JAMA Neurol"},{"key":"ref11","doi-asserted-by":"publisher","first-page":"478","DOI":"10.1056\/NEJMc2215148","article-title":"Multiple Cerebral Hemorrhages in a Patient Receiving Lecanemab and Treated with t-PA for Stroke","volume":"388","author":"NJ Reish","year":"2023","journal-title":"N Engl J Med"},{"key":"ref12","doi-asserted-by":"publisher","DOI":"10.1002\/dad2.70273","article-title":"Initial real-world experience with lecanemab prescribing patterns in Japan: The Longevity Improvement & Fair Evidence (LIFE) Study","volume":"18","author":"K Kawaguchi","year":"2026","journal-title":"Alzheimers Dement (Amst)"},{"key":"ref13","doi-asserted-by":"publisher","first-page":"119","DOI":"10.1186\/s13195-025-01763-1","article-title":"Lecanemab in clinical practice: real-world outcomes in early Alzheimer\u2019s disease","volume":"17","author":"N Bregman","year":"2025","journal-title":"Alz Res Therapy"},{"key":"ref15","doi-asserted-by":"publisher","first-page":"14","DOI":"10.1186\/s13195-024-01666-7","article-title":"evoke and evoke+: design of two large-scale, double-blind, placebo-controlled, phase 3 studies evaluating efficacy, safety, and tolerability of semaglutide in early-stage symptomatic Alzheimer\u2019s disease","volume":"17","author":"JL Cummings","year":"2025","journal-title":"Alz Res Therapy"},{"key":"ref16","doi-asserted-by":"publisher","DOI":"10.1002\/trc2.70098","article-title":"Alzheimer\u2019s disease drug development pipeline: 2025","volume":"11","author":"JL Cummings","year":"2025","journal-title":"Alzheimers Dement (N Y)"},{"key":"ref17","doi-asserted-by":"publisher","DOI":"10.1002\/alz.70662","article-title":"Donanemab in preclinical Alzheimer\u2019s disease: Screening and baseline data from TRAILBLAZER-ALZ 3","volume":"21","author":"R Yaari","year":"2025","journal-title":"Alzheimers Dement"},{"key":"ref18","doi-asserted-by":"publisher","first-page":"A50","DOI":"10.1136\/jnnp-2025-ABN.162","article-title":"162 TRAILRUNNER-ALZ3: a phase-3 study of subcutaneous remternetug in preclinical and MCI Alzheimer\u2019s disease population","volume":"96","author":"B Kevin","year":"2025","journal-title":"J Neurol Neurosurg Psychiatry"},{"key":"ref19","doi-asserted-by":"publisher","DOI":"10.1002\/alz.70147","article-title":"Long-term metformin use for Alzheimer\u2019s disease prevention?","volume":"21","author":"T Daly","year":"2025","journal-title":"Alzheimers Dement"},{"key":"ref20","doi-asserted-by":"publisher","first-page":"65","DOI":"10.1186\/s13195-023-01214-9","article-title":"The effect of music therapy on cognitive functions in patients with Alzheimer\u2019s disease: a systematic review of randomized controlled trials","volume":"15","author":"M Bleibel","year":"2023","journal-title":"Alz Res Therapy"},{"key":"ref22","doi-asserted-by":"publisher","first-page":"212","DOI":"10.1016\/j.jshs.2021.05.003","article-title":"Comparative efficacy of various exercise interventions on cognitive function in patients with mild cognitive impairment or dementia: A systematic review and network meta-analysis","volume":"11","author":"X Huang","year":"2022","journal-title":"J Sport Health Sci"},{"key":"ref23","doi-asserted-by":"publisher","first-page":"480","DOI":"10.1186\/s12877-024-05060-8","article-title":"Effective dosage and mode of exercise for enhancing cognitive function in Alzheimer\u2019s disease and dementia: a systematic review and Bayesian Model-Based Network Meta-analysis of RCTs","volume":"24","author":"Y Yuan","year":"2024","journal-title":"BMC Geriatr"},{"key":"ref24","doi-asserted-by":"publisher","first-page":"681","DOI":"10.1001\/jama.2025.12923","article-title":"Structured vs Self-Guided Multidomain Lifestyle Interventions for Global Cognitive Function: The US POINTER Randomized Clinical Trial","volume":"334","author":"LD Baker","year":"2025","journal-title":"JAMA"}],"container-title":["DMW - Deutsche Medizinische Wochenschrift"],"original-title":[],"language":"de","link":[{"URL":"http:\/\/www.thieme-connect.de\/products\/ejournals\/pdf\/10.1055\/a-2676-7649.pdf","content-type":"unspecified","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2026,5,29]],"date-time":"2026-05-29T22:38:33Z","timestamp":1780094313000},"score":1,"resource":{"primary":{"URL":"http:\/\/www.thieme-connect.de\/DOI\/DOI?10.1055\/a-2676-7649"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2026,5,29]]},"references-count":21,"journal-issue":{"issue":"12","published-online":{"date-parts":[[2026,5,29]]},"published-print":{"date-parts":[[2026,6]]}},"URL":"https:\/\/doi.org\/10.1055\/a-2676-7649","archive":["Portico","CLOCKSS"],"relation":{},"ISSN":["0012-0472","1439-4413"],"issn-type":[{"value":"0012-0472","type":"print"},{"value":"1439-4413","type":"electronic"}],"subject":[],"published":{"date-parts":[[2026,5,29]]}}}